These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15006017)

  • 1. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
    Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
    Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS; Aslam M; Naveed AK; Razi MS
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
    Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
    Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
    Durbin RJ
    Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
    Gegick CG; Altheimer MD
    Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of combined therapy for type 2 diabetes.
    Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
    Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.